LPL Financial
ABCL icon

LPL Financial’s AbCellera Biologics ABCL Stock Holding History

LPL Financial’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$29.6K – 5158
2024
Q2 		$29.6K Buy
+10,000
New +$37.8K ﹤0.01% 4902

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

LPL Financial's ABCL Position: Q2 2026 in Review

LPL Financial reduced its AbCellera Biologics (ABCL) stake by 27% in Q2 2026, selling an estimated $158K and leaving 89,501 shares worth $703K. The position accounts for ﹤0.01% of the portfolio, ranked #4742.

LPL Financial first reported a position in ABCL in Q1 2024 and has held it in 8 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • LPL Financial held 89,501 shares of AbCellera Biologics worth $703K as of Q2 2026.
  • LPL Financial sold 32,312 AbCellera Biologics shares in Q2 2026, an estimated $158K.
  • AbCellera Biologics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #4742 holding.
  • LPL Financial first reported a position in AbCellera Biologics in Q1 2024 and has held it in 8 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.